Skip to content

Acute respiratory distress syndrome comparative immune profiling

Acute respiratory distress syndrome patients with or without SARS CoV2 infection comparative immune profilng

Acute respiratory distress syndrome (ARDS) is the main complication of coronavirus disease 2019 (COVID-19), requiring admission to the intensive care unit (ICU). Despite extensive immune profiling of COVID-19 patients, to what extent COVID-19-associated ARDS differs from other causes of ARDS remains unknown. To address this question, here, we build 3 cohorts of patients categorized in COVID-19ARDS+, COVID-19+ARDS+, and COVID-19+ARDS, and compare, by high-dimensional mass cytometry, their immune landscape. A cell signature associating S100A9/calprotectin-producing CD169+ monocytes, plasmablasts, and Th1 cells is found in COVID-19+ARDS+, unlike COVID-19ARDS+ patients. Moreover, this signature is essentially shared with COVID-19+ARDS patients, suggesting that severe COVID-19 patients, whether or not they experience ARDS, display similar immune profiles. We show an increase in CD14+HLA-DRlow and CD14lowCD16+ monocytes correlating to the occurrence of adverse events during the ICU stay. We demonstrate that COVID-19-associated ARDS displays a specific immune profile and may benefit from personalized therapy in addition to standard ARDS management. Read more: 

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

Recent News

NextGen Omics Boston Conference

Scailyte will be attending the upcoming NextGen Omics Boston conference, taking place on March 30-31

Read more

Recent News

Vijay Tiwari is appointed as Chair of the Scientific Advisory Board

Vijay Tiwari is appointed as the Chair of Scailyte's Scientific Advisory Board

Read more

Recent News

Endometriosis interview series

We mark Endometriosis Awareness Month, and Scailyte is proud to support this cause with the “Endom

Read more

Recent News

Scailyte Announces a Collaboration with Turnstone Biologics

Scailyte Announces Collaboration with Turnstone Biologics to Identify Biomarker Signatures in Solid

Read more

Recent News

BIO-Europe Spring 2023

We will be attending the 17th annual BIO-Europe Spring taking place from 20-22 March 2023 in Basel.

Read more

Recent News

Deciphering Disease Mechanisms Through Functional Genomics

Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica

Read more

Recent News

International Women's Day 2023

Scailyte celebrates International Women’s day and praises all women Scailyters: smart, trailblazin

Read more

Recent News

Diana Stoycheva and Sarah Carl at Biomarkers 2023

We are excited to announce our attendance at Oxford Global Conferences' Biomarkers 2023! Our team, i

Read more

Recent News

01 /04

NextGen Omics Boston Conference

Scailyte will be attending the upcoming NextGen Omics Boston conference, taking place on March 30-31

Read more

Vijay Tiwari is appointed as Chair of the Scientific Advisory Board

Vijay Tiwari is appointed as the Chair of Scailyte's Scientific Advisory Board

Read more

Recent News

02 /04

Endometriosis interview series

We mark Endometriosis Awareness Month, and Scailyte is proud to support this cause with the “Endom

Read more

Scailyte Announces a Collaboration with Turnstone Biologics

Scailyte Announces Collaboration with Turnstone Biologics to Identify Biomarker Signatures in Solid

Read more

Recent News

03 /04

BIO-Europe Spring 2023

We will be attending the 17th annual BIO-Europe Spring taking place from 20-22 March 2023 in Basel.

Read more

Deciphering Disease Mechanisms Through Functional Genomics

Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica

Read more

Recent News

04 /04

International Women's Day 2023

Scailyte celebrates International Women’s day and praises all women Scailyters: smart, trailblazin

Read more

Diana Stoycheva and Sarah Carl at Biomarkers 2023

We are excited to announce our attendance at Oxford Global Conferences' Biomarkers 2023! Our team, i

Read more

Recent News